{"id":"vyvanse-lisdexamphetamine","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Decreased appetite"},{"rate":"25-35","effect":"Insomnia"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Anxiety"},{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Elevated blood pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lisdexamphetamine is an inactive compound that requires enzymatic conversion by red blood cells to release active dexamphetamine. Once converted, dexamphetamine acts as a sympathomimetic amine that enhances catecholamine activity by stimulating release of norepinephrine and dopamine from presynaptic neurons and inhibiting their reuptake, leading to increased synaptic concentrations of these neurotransmitters. This mechanism improves attention, focus, and impulse control in patients with ADHD.","oneSentence":"Lisdexamphetamine is a prodrug that is converted in the body to dexamphetamine, which increases the release and blocks the reuptake of norepinephrine and dopamine in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:02.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults"},{"name":"Moderate to severe binge eating disorder"}]},"trialDetails":[{"nctId":"NCT03497169","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2016-11-02","conditions":"Obesity, Morbid","enrollment":12},{"nctId":"NCT05957055","phase":"PHASE2","title":"Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2024-02-05","conditions":"Attention Deficit Disorder with Hyperactivity, Diabetes Mellitus, Type 1","enrollment":150},{"nctId":"NCT03337646","phase":"PHASE4","title":"Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism","status":"COMPLETED","sponsor":"JPM van Stralen Medicine Professional","startDate":"2018-09-26","conditions":"Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder","enrollment":48},{"nctId":"NCT02136147","phase":"","title":"ADHD Medication and Predictors of Treatment Outcome","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-06","conditions":"Attention Deficit Disorder With Hyperactivity (ADHD)","enrollment":632},{"nctId":"NCT04946461","phase":"","title":"The Day-time Response Variation of (Lis)Dexamphetamine","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2021-07-01","conditions":"Adhd","enrollment":16},{"nctId":"NCT02668926","phase":"PHASE1","title":"Endocrine and Emotional Effects of Lisdexamfetamine and d-Amphetamine.","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-05","conditions":"Healthy","enrollment":24},{"nctId":"NCT01816074","phase":"PHASE4","title":"Sequencing Treatments for Mothers With ADHD and Their At - Risk Children","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2012-10","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":53},{"nctId":"NCT00573534","phase":"PHASE4","title":"Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-03","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lisdexamfetamine"],"phase":"marketed","status":"active","brandName":"Vyvanse (lisdexamphetamine)","genericName":"Vyvanse (lisdexamphetamine)","companyName":"Seattle Children's Hospital","companyId":"seattle-children-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vyvanse (lisdexamphetamine) is a medication used to treat Attention Deficit Disorder With Hyperactivity (ADHD), Autism Spectrum Disorder, and Obesity, as indicated by ClinicalTrials.gov. According to ChEMBL, Vyvanse works by inhibiting the reuptake of dopamine and norepinephrine in the brain, which are neurotransmitters involved in attention and impulse control.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}